Department of Health and Human Services November 14, 2024 – Federal Register Recent Federal Regulation Documents

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public workshop entitled "Patient- Focused Drug Development: Workshop to Discuss Methodologic and Other Challenges Related to Patient Experience Data." The purpose of the public workshop is to discuss methodological challenges related to patient experience data, and other areas of greatest interest or concern to public stakeholders.

This notice announces the monthly actuarial rates for aged (age 65 and over) and disabled (under age 65) beneficiaries enrolled in Part B of the Medicare Supplementary Medical Insurance (SMI) program beginning January 1, 2025. In addition, this notice announces the monthly premium for aged and disabled beneficiaries, the deductible for 2025, and the income-related monthly adjustment amounts to be paid by beneficiaries with modified adjusted gross income above certain threshold amounts. The monthly actuarial rates for 2025 are $368.10 for aged enrollees and $487.80 for disabled enrollees. The standard monthly Part B premium rate for all enrollees for 2025 is $185.00, which is equal to 50 percent of the monthly actuarial rate for aged enrollees (or approximately 25 percent of the expected average total cost of Part B coverage for aged enrollees) plus the $0.90 repayment amount required under current law. (The 2025 premium is 5.9 percent or $10.30 higher than the 2024 standard premium rate of $174.70, which included a $3.00 repayment amount.) The Part B deductible for 2025 is $257.00 for all Part B beneficiaries. If a beneficiary has to pay an income-related monthly adjustment amount, that individual will have to pay a total monthly premium of about 35, 50, 65, 80, or 85 percent of the total cost of Part B coverage plus a repayment amount of $1.30, $1.80, $2.30, $2.90, or $3.10, respectively. Beginning in 2023, certain Medicare enrollees who are 36 months post kidney transplant, and therefore no longer eligible for full Medicare coverage, can elect to continue Part B coverage of immunosuppressive drugs by paying a premium. For 2025, the standard monthly Part B immunosuppressive drug coverage only premium is $110.40.

This notice announces the inpatient hospital deductible and the hospital and extended care services coinsurance amounts for services furnished in calendar year (CY) 2025 under Medicare's Hospital Insurance Program (Medicare Part A). The Medicare statute specifies the formulae used to determine these amounts. For CY 2025, the inpatient hospital deductible will be $1,676. The daily coinsurance amounts for CY 2025 will be as follows: $419 for the 61st through 90th day of hospitalization in a benefit period; $838 for lifetime reserve days; and $209.50 for the 21st through 100th day of extended care services in a skilled nursing facility in a benefit period.

The National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of licensing and collaboration opportunities for the inventions listed below, which are owned by an agency of the U.S. Government and are available for license and collaboration in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.